| Economic burden of attention-deficit/hyperactivity disorder among pediatric patients in the United States K Gupte-Singh, RR Singh, KA Lawson Value in Health 20 (4), 602-609, 2017 | 80 | 2017 |
| Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition—a pooled analysis of patients with advanced melanoma MM Regan, L Werner, S Rao, K Gupte-Singh, FS Hodi, JM Kirkwood, ... Journal of Clinical Oncology 37 (35), 3350, 2019 | 65 | 2019 |
| Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect … MB Atkins, A Tarhini, M Rael, K Gupte-Singh, E O’Brien, C Ritchings, ... Immunotherapy 11 (7), 617-629, 2019 | 33 | 2019 |
| Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma A Tarhini, D McDermott, A Ambavane, K Gupte-Singh, V Aponte-Ribero, ... Immunotherapy 11 (4), 283-295, 2019 | 28 | 2019 |
| Prospective case-crossover study investigating the possible association between nonarteritic anterior ischemic optic neuropathy and phosphodiesterase type 5 inhibitor exposure EM Flahavan, H Li, K Gupte-Singh, RT Rizk, DD Ruff, JL Francis, ... Urology 105, 76-84, 2017 | 26 | 2017 |
| Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost–effectiveness analysis A Tarhini, A Benedict, D McDermott, S Rao, A Ambavane, K Gupte-Singh, ... Immunotherapy 10 (14), 1241-1252, 2018 | 25 | 2018 |
| Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA A Tarhini, C Atzinger, K Gupte-Singh, C Johnson, C Macahilig, S Rao Journal of Comparative Effectiveness Research 8 (7), 461-473, 2019 | 22 | 2019 |
| Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time … DF McDermott, R Shah, K Gupte-Singh, J Sabater, L Luo, M Botteman, ... Quality of Life Research 28, 109-119, 2019 | 19 | 2019 |
| Adherence to anticoagulant therapy in pediatric patients hospitalized with pulmonary embolism or deep vein thrombosis: a retrospective cohort study RR Singh, KR Gupte-Singh, JP Wilson, BS Moffett Clinical and Applied Thrombosis/Hemostasis 22 (3), 260-264, 2016 | 13 | 2016 |
| Indirect treatment comparison of nivolumab versus observation or ipilimumab as adjuvant therapy in resected melanoma using pooled clinical trial data M Freeman, KA Betts, S Jiang, EX Du, K Gupte-Singh, Y Lu, S Rao, ... Advances in therapy 36, 2783-2796, 2019 | 10 | 2019 |
| Real-world effectiveness of Nivolumab monotherapy after prior systemic therapy in advanced non–small-cell lung cancer in the United States DD Stenehjem, SJ Lubinga, K Gupte-Singh, Y Zhang, TK Le, JR Penrod, ... Clinical Lung Cancer 22 (1), e35-e47, 2021 | 7 | 2021 |
| Non–small cell lung cancer patient preferences for first-line treatment: a discrete choice experiment JP MacEwan, K Gupte-Singh, LM Zhao, KL Reckamp MDM policy & practice 5 (1), 2381468320922208, 2020 | 6 | 2020 |
| Patterns of antiepileptic drug use in patients with potential refractory epilepsy in Texas Medicaid K Gupte-Singh, JP Wilson, JC Barner, KM Richards, KL Rascati, ... Epilepsy & Behavior 87, 108-116, 2018 | 6 | 2018 |
| Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma. AN Shoushtari, ML Freeman, KA Betts, K Gupte-Singh, EX Du, ... Journal of Clinical Oncology 36 (15_suppl), 9593-9593, 2018 | 6 | 2018 |
| Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison E Swallow, T Pham, O Patterson-Lomba, L Yin, A Gomez-Lievano, J Liu, ... Multiple Sclerosis and Related Disorders 71, 104551, 2023 | 5 | 2023 |
| S694 comparative efficacy and safety of ozanimod vs adalimumab and vedolizumab in patients with moderately to severely active ulcerative colitis MC Dubinsky, KA Betts, K LaPensee, D Eren, D Kim-Romo, L Yin, W Tang, ... Official journal of the American College of Gastroenterology| ACG 116, S314, 2021 | 5 | 2021 |
| Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma. ML Freeman, AN Shoushtari, KA Betts, K Gupte-Singh, EX Du, ... Journal of Clinical Oncology 36 (15_suppl), 9594-9594, 2018 | 5 | 2018 |
| Impact of comorbid depression on medication adherence and asthma-related healthcare costs in Texas Medicaid patients with asthma K Gupte-Singh, G Kim, JC Barner Journal of Pharmaceutical Health Services Research 6 (4), 197-205, 2015 | 5 | 2015 |
| PCN21 Impact of anticholinergic load of medications on the length of stay of cancer patients in hospice care KP Gupte, W Wu Value in Health 15 (4), A211, 2012 | 5* | 2012 |
| Matching-adjusted indirect comparison of nivolumab + ipilimumab and BRAF+MEK inhibitors for the treatment of BRAF-mutant treatment-naive advanced melanoma MB Atkins, D McDermott, A Tarhini, M Rael, K Gupte-Singh, E O'Brien, ... Cancer Research 78 (13_Supplement), 3639-3639, 2018 | 4 | 2018 |
